Systematic review and meta-analysis of short-versus long-acting granulocyte colony-stimulating factors for reduction of chemotherapy-induced febrile neutropenia
P Cornes, P Gascon, S Chan, K Hameed… - Advances in …, 2018 - Springer
Introduction Short-and long-acting granulocyte-colony stimulating factors (G-CSFs) are
approved for the reduction of febrile neutropenia. A systematic literature review was …
approved for the reduction of febrile neutropenia. A systematic literature review was …
Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: a …
S Mitchell, X Li, M Woods, J Garcia… - Journal of Oncology …, 2016 - journals.sagepub.com
Introduction Febrile neutropenia (FN) is a serious side-effect of myelosuppressive
chemotherapy. Several clinical trials and observational studies have evaluated the effects of …
chemotherapy. Several clinical trials and observational studies have evaluated the effects of …
Cost-effectiveness of granulocyte colony-stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) in patients with cancer
MS Aapro, S Chaplin, P Cornes, S Howe, H Link… - Supportive Care in …, 2023 - Springer
Purpose Clinical practice guidelines recommend the use of all approved granulocyte colony-
stimulating factors (G-CSFs), including filgrastim and pegfilgrastim, as primary febrile …
stimulating factors (G-CSFs), including filgrastim and pegfilgrastim, as primary febrile …
[HTML][HTML] A multicentre, randomised trial comparing schedules of G-CSF (filgrastim) administration for primary prophylaxis of chemotherapy-induced febrile neutropenia …
Background The optimal duration of filgrastim as primary febrile neutropenia (FN)
prophylaxis in early breast cancer patients is unknown, with 5, 7 or 10 days being commonly …
prophylaxis in early breast cancer patients is unknown, with 5, 7 or 10 days being commonly …
Biosimilar pegfilgrastim: improving access and optimising practice to supportive care that enables cure
P Cornes, P Gascon, AG Vulto, M Aapro - BioDrugs, 2020 - Springer
Febrile neutropenia (FN) is a serious complication of chemotherapy, which can cause
significant morbidity and mortality, result in dose delays and reductions and, ultimately …
significant morbidity and mortality, result in dose delays and reductions and, ultimately …
Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related …
TC Bond, E Szabo, S Gabriel… - Journal of Oncology …, 2018 - journals.sagepub.com
Background Granulocyte colony-stimulating factors are effective at reducing the risk and
duration of neutropenia. The current meta-analysis compared the neutropenia-related …
duration of neutropenia. The current meta-analysis compared the neutropenia-related …
Clinical outcomes of treatment with filgrastim versus a filgrastim biosimilar and febrile neutropenia-associated costs among patients with nonmyeloid cancer …
LS Schwartzberg, LS Lal, S Balu, K Campbell… - Journal of Managed …, 2018 - jmcp.org
BACKGROUND: Granulocyte colony-stimulating factors such as filgrastim are used to
decrease the incidence of febrile neutropenia (FN) among patients with nonmyeloid cancers …
decrease the incidence of febrile neutropenia (FN) among patients with nonmyeloid cancers …
Management of chemotherapy-induced neutropenia in patients with cancer: 2019 guidelines of the Italian Medical Oncology Association (AIOM)
AC Tralongo, A Antonuzzo, P Pronzato… - Tumori …, 2020 - journals.sagepub.com
Neutropenia is the most frequent side effect of commercially available myelosuppressive
drugs and its most significant complication is febrile neutropenia. It is associated with …
drugs and its most significant complication is febrile neutropenia. It is associated with …
Real-world cost–effectiveness of primary prophylaxis with G-CSF biosimilars in patients at intermediate/high risk of febrile neutropenia
P Cornes, J Kelton, R Liu, O Zaidi, J Stephens… - Future …, 2022 - Taylor & Francis
Background: Real-world data suggests superiority of pegfilgrastim (PEG) over filgrastim (FIL)
in reducing the incidence of chemotherapy-induced febrile neutropenia (FN), probably …
in reducing the incidence of chemotherapy-induced febrile neutropenia (FN), probably …
Prescription patterns of granulocyte colony–stimulating factors in patients with breast cancer: A real-world study
Background and objectives Myelosuppressive chemotherapy is effective for breast cancer
but carries a potential risk of febrile neutropenia (FN). Clinical practice guidelines have …
but carries a potential risk of febrile neutropenia (FN). Clinical practice guidelines have …